

Freedom of Information Act 2000 - Request Reference FoI/22/511
SACT Treatments

1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Alpelisib + Fulvestrant
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
- Atezolizumab + Nab-paclitaxel/Paclitaxel
- Capecitabine as a single agent
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fulvestrant as a single agent
- Lapatinib
- Neratinib
- Parp Inhibitors (Olaparib/Talazoparib)
- Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
- Palbociclib + Fulvestrant
- Pembrolizumab
- Platinum (e.g. carboplatin or cisplatin) as a single agent
- Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Sacituzumab Govitecan
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Taxane and/or Anthracycline in combination
- Trastuzumab as a single agent or in combination
- Trastuzumab emtansine
- Trastuzumab deruxtecan
- Any other active systemic anti-cancer therapy

2. Does your trust participate in any clinical trials for breast cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Response details:

Cardiff and Vale University Health Board (the UHB) does not hold this information. Under Section 16 of the FOIA, which provides us with the duty to advise and assist, the UHB can inform you that these treatments are provided by Velindre Cancer Centre, please see their contact details below:

foi.vunhst@wales.nhs.uk

Or,

Velindre NHS Trust Headquarters.
Unit 2 Charnwood Court,
Parc Nantgarw,
Nantgarw,
Cardiff.
CF15 7QZ